Certain identified information has been excluded from the exhibit because it is both (i) not material and (ii) is the type of information that the registrant treats as private or confidential. Double asterisks denote omissions. AMENDED AND RESTATED...Patent & Technology License Agreement • January 25th, 2024 • Aileron Therapeutics Inc • Pharmaceutical preparations • Texas
This Amended and Restated Patent and Technology License Agreement (“Agreement”), effective as of December 19, 2013, is between the Board of Regents of The University of Texas System, an agency of the State of Texas whose address is 201 West 7th St. Austin, TX 78701 (“Board”), on behalf of The University of Texas Health Science Center at Tyler (“UTHSCT”) (with Board on behalf of UTHSCT as “Licensor”), and Lung Therapeutics, Inc., a Texas Corporation, with its principal place of business at P.O. Box 150183, Austin, Texas 78715 (“Licensee”) (collectively, “Parties”, or singly, “Party”).
Certain identified information has been excluded from the exhibit because it is both (i) not material and (ii) is the type of information that the registrant treats as private or confidential. Double asterisks denote omissions. LICENSE AGREEMENT by...License Agreement • January 25th, 2024 • Aileron Therapeutics Inc • Pharmaceutical preparations • New York
THIS LICENSE AGREEMENT, (the “Agreement”) effective as of March 8, 2018, (the “Effective Date”) is entered into by and between Lung Therapeutics, Inc., having and address at 2801 Via Fortuna, Suite 425, Austin, TX 78746 (herein called “Licensee”), and Vivarta Therapeutics, L.L.C., a North Carolina limited liability company, having its principal place of business at 203 Woodside Glen Place, Cary, NC 27519 (herein called “Licensor”). Licensee and Licensor are sometimes hereinafter referred to collectively as the “Parties” or individually as a “Party”.
Certain identified information has been excluded from the exhibit because it is both (i) not material and (ii) is the type of information that the registrant treats as private or confidential. Double asterisks denote omissions. EXCLUSIVE LICENSE...Exclusive License Agreement • January 25th, 2024 • Aileron Therapeutics Inc • Pharmaceutical preparations • New York
THIS EXCLUSIVE LICENSE AGREEMENT (the “Agreement”) is entered into as of November 12, 2020 (the “Effective Date”) by and among LUNG THERAPEUTICS, INC., a Texas corporation, having an address of 2600 Via Fortuna, Suite 360, Austin, Texas 78746, USA (“Lung Tx”) and TAIHO PHARMACEUTICAL CO., LTD., a company incorporated under the laws of Japan, having an address of 1-27 Kandanishiki-cho, Chiyoda-ku, Tokyo, Japan 101-8444 (“Taiho”). Lung Tx and Taiho may be referred to herein individually as a “Party” or collectively, as the “Parties.”
Certain identified information has been excluded from the exhibit because it is both (i) not material and (ii) is the type of information that the registrant treats as private or confidential. Double asterisks denote omissions. Patent License...Patent License Agreement • January 25th, 2024 • Aileron Therapeutics Inc • Pharmaceutical preparations • Texas
This Patent License Agreement is between the Licensor and the Licensee identified below (collectively, “Parties”, or singly, “Party”).
Certain identified information has been excluded from the exhibit because it is both (i) not material and (ii) is the type of information that the registrant treats as private or confidential. Double asterisks denote omissions. AMENDED AND RESTATED...License Agreement • January 25th, 2024 • Aileron Therapeutics Inc • Pharmaceutical preparations • South Carolina
THIS AMENDED AND RESTATED AGREEMENT, (the “Agreement”) effective as of September 1, 2018 (the “Amendment Date”), is entered into by and between Lung Therapeutics, Inc., having and address at 2801 Via Fortuna, Suite 425, Austin, TX 78746 (herein called “Licensee”), and MUSC Foundation for Research Development, a 501(c)(3) South Carolina not for profit corporation, having its principal place of business at 135 Cannon Street, Suite 101L, Charleston, SC 29425 (herein called “Licensor”). Licensee and Licensor are sometimes hereinafter referred to collectively as the “Parties” or individually as a “Party”.
